12-month outcomes of cabotegravir plus rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and patient-reported outcomes from people with HIV-1 in the German CARLOS cohort

AUTHORS

C. Jonsson-Oldenbüttel¹, S. Noe¹, C. Wyen², J. Borch³, K. Ummard-Berger⁴, N. Postel⁵, S. Scholten⁶, K.M. Dymek⁷, B. Westermayer⁸, P. de los Rios⁹, J. Scherzer⁷


INSTITUTIONS

¹MVZ München am Goetheplatz, Munich, Germany, ²Praxis am Ebertplatz, Cologne, Germany, ³Praxis Goldstein, Berlin, Germany, ⁴UBN/Praxis, Berlin, Germany, ⁵Prinzmed, Practice for Infectious Diseases, Munich, Germany, ⁶Praxis Hohenstaufenring, Cologne, Germany, ⁷ViiV Healthcare, Munich, Germany, ⁸GSK, Munich, Germany, ⁹ViiV Healthcare, Montreal, Canada